Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Pegcetacoplan, an investigational, targeted C3 therapy, has the potential to become the first treatment for GA, a leading cause of blindness worldwide WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE)...
-
Generated $5.3 million in EMPAVELI™ (pegcetacoplan) net product revenues Presented Phase 3 DERBY and OAKS results in geographic atrophy (GA); on track for NDA submission in 1H 2022Received positive...
-
Results from positive Phase 3 PRINCE study in treatment-naïve patients with PNH accepted for oral presentation In new analysis, EMPAVELI demonstrated clinically meaningful improvements in key markers...
-
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
-
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
-
WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that...
-
WALTHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
-
Results further support the efficacy and safety profile of pegcetacoplan, an investigational, targeted C3 therapy, with monthly and every-other-month treatment Pegcetacoplan has the potential to...
-
WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
-
OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052),...